24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Corporate
Appointments
Tech Gateways
@Finance
Ctech Testimonials
Projects
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Patent
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
18:20
The World Cup warning: Riots don’t start in the streets. They start online
18:07
“There’s a price where you have to say yes”: CyberArk founder on the $25 billion Palo Alto deal
14:18
"If there is no significant change, we will see a 25%-30% reduction in high-tech's workforce"
13:32
“There is no better solution for Zim than the one we created”
More stories
Buzz
Most popular
Daily
Weekly
1
"If an engineer in Ireland costs 20% less, it is clearly part of the consideration when deciding where to expand"
2
Iron Dome and Iron Beam maker Rafael unveils new weapon against the drone threat
3
"If there is no significant change, we will see a 25%-30% reduction in high-tech's workforce"
4
Echo: “Employees have become very good at identifying performative culture”
5
Unicorn Artlist to cut 200 jobs, 40% of workforce, despite surpassing $300 million ARR
More news
Patent
3 stories about Patent
Startup Contests Are Not for Everyone
22.10.17
|
Zachi Zach
If not carefully selected, a startup contest could hold more risk than value
Teva’s Stock Drops After Approval of Copaxone Competitors
08.10.17
|
Lilach Baumer
A day after Mylan announced FDA approval for its generic versions of Copaxone, drug companies Synthon and Alvogen announce European approval for their 40 mg/ml generic versions of Teva's blockbuster drug
Your First Investor Meeting, a Survival Guide
27.09.17
|
Zachi Zach
Your first meeting with a potential investor is critical because you probably won’t get another chance. Do your homework
Previous Articles